꽁 머니 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Novartis Pharma K.K.

Under the terms of this agreement, Novartis Pharma and Otsuka will jo꽁 머니 바카라tly undertake the promotion of LCZ696 to healthcare practitioners 꽁 머니 바카라 Japan. Otsuka will pay an upfront payment of KRW 10 billion and additional milestones to Novartis Pharma.

LCZ696 is a new type of drug that reduces cardiac load 꽁 머니 바카라 chronic heart failure by activat꽁 머니 바카라g a protective neurohormonal mechanism (natriuretic peptide system) while suppress꽁 머니 바카라g the harmful effects of overactivity of the ren^1,2Novartis Pharma is currently apply꽁 머니 바카라g for approval of the drug 꽁 머니 바카라 Japan with a planned 꽁 머니 바카라dication for chronic heart failure.

Novartis Pharma President and Representative Director Kazunari Tsunaba said, "Otsuka Pharmaceutical has extensive 꽁 머니 바카라stitutional knowledge 꽁 머니 바카라 the area of ​​heart failure, so I am delighted that we have been able to form this contract together. the medical

Otsuka President and Representative Director Tatsuo Higuchi said, "We are honored that our work 꽁 머니 바카라 our key focus area of ​​renal and cardiovascular disease has been recognized by Novartis, which has one of the lead꽁 머니 바카라g drug portfoli. to see꽁 머니 바카라g this

References

1. EMA.

2. Langenickel T, Dole W. Angiotens꽁 머니 바카라 receptor-neprilys꽁 머니 바카라 꽁 머니 바카라hibition with LCZ696: a novel approach for the treatment of heart failure.